PCV59 Cost-Effectiveness of Dabigatran Etexilate Versus Apirin Plus Clopidogrel Combination in Stroke Prevention in Atrial Fibrillation (SPAF): Russian Payer Perspective

Abstract

OBJECTIVES:To compare cost-effectiveness of rosuvastatin (RSV) versus ezetimibe/simvastatin (E/S) in achieving LDL-C goals (NCEP- ATP III 2001 and 2004 guidelines), in daily outpatient practice in Mexico. METHODS: Retrospective study. From January 2004 to December 2010, outpatient medical records in 15 Mexican hospitals/clinics were reviewed to identify patients with dyslipidemia and their corresponding serum lipid measurements documented before receiving drug therapy with either RSV (5mg, 10mg, or 20mg once daily) or E/S (5/5mg, 10/10mg, 10/ 20mg or 10/40mg once daily); and lipid levels recorded at least after 8 weeks of treatment. The efficacy was assessed by a) the proportion of patients who achieved the LDL-C goal, and b) the percent reduction in LDL-C after 8 weeks of treatment. A cost-effectiveness analysis was performed from an institutional perspective, using the exchange rate of August 2011 of 12.2424 pesos/USD. RESULTS: Using ATP III 2001 criteria, percentage of patients who reached LDL-C goals was RSV: 81.3% and E/S 77.1% (p ϭ 0.2972). Using ATP III 2004 criteria were: RSV, 61.3% vs. E/S, 58.5% (pϭ0.2548). The average treatment cost was statistically significant higher for E/S patients (239.49 USD) versus 192.74 USD for RSV patients (pϭ0.0033).